These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36411743)

  • 1. Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for
    Li D; Liu J; Zhang X; Han J; Jin H; Wang L; Feng L; Fan Z; Zuo J; Wang Y
    Cancer Manag Res; 2022; 14():3175-3179. PubMed ID: 36411743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Li J; Wang Q; Ge J; Tian Y; Yao W
    Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
    Yamazoe M; Ozasa H; Tsuji T; Funazo T; Yoshida H; Hashimoto K; Hosoya K; Ogimoto T; Ajimizu H; Yoshida H; Itotani R; Sakamori Y; Kuninaga K; Aoki W; Hirai T
    Cancer Sci; 2023 Feb; 114(2):546-560. PubMed ID: 36285485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
    Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
    Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
    Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
    Xue Y; Ren Y; Yan B; Li Z; Huang C
    Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
    Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
    ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
    Sehgal K; Piper-Vallillo AJ; Viray H; Khan AM; Rangachari D; Costa DB
    Precis Cancer Med; 2020 Jun; 3():. PubMed ID: 32776005
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
    Schneider JL; Muzikansky A; Lin JJ; Krueger EA; Lennes IT; Jacobson JO; Cheng M; Heist RS; Piotrowska Z; Gainor JF; Shaw AT; Dagogo-Jack I
    JTO Clin Res Rep; 2022 Jul; 3(7):100347. PubMed ID: 35815322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib-Resistant
    Begum P; Cui W; Popat S
    JTO Clin Res Rep; 2022 Sep; 3(9):100376. PubMed ID: 35966191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
    Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
    Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
    Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
    Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
    Front Oncol; 2022; 12():911303. PubMed ID: 35814395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
    Facchinetti F; Levy A; Ammari S; Naltet C; Lavaud P; Aldea M; Vasseur D; Planchard D; Besse B
    Cancer Manag Res; 2021; 13():2805-2810. PubMed ID: 33814929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.